BeiGene reports 2022 revenue of $1.42B, R&D spend $1.64B in STAR Market filing

BeOne Medicines Ltd.

Total revenue $1.416B (2021: $1.176B); China revenue $840M (67.1% margin), Ex-China $576M (98.3% margin).
R&D expenses $1.641B vs $1.459B in 2021; key product spend: Zanubrutinib $127M, Tislelizumab $88.9M, Ociperlimab $106.6M.
Production/sales/inventory: 3.28M vials produced, 2.67M sold, 1.54M in stock as of Dec 31, 2022.
Filed PRC GAAP vs U.S. GAAP reconciliation; differences in share-based comp (accelerated vs straight-line) and lease accounting.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BeOne Medicines Ltd. reported the year ended December 31, 2022 results: revenue 1,415,921.

Period: the year ended December 31, 2022
Revenue: 1,415,921
Result: reported results

Exact text from the filing

For the year ended December 31, 2022 For the year ended December 31, 2021 By Region Revenue COGS Gross Margin ratio Revenue COGS Gross Margin ratio China 840,032 276,729 67.1% 517,173 162,976 68.5% Ex-China 575,889 9,746 98.3% 659,110 1,930 99.7% Total 1,415,921 286,475 1,176,283 164,906

View on SEC.gov

Browse all earnings releases →

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001651308-23-000061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.